Trials / Recruiting
RecruitingNCT07277231
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Previously Untreated Chronic Lymphocytic Leukemia
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 500 (estimated)
- Sponsor
- BeOne Medicines · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sonrotoclax | Administered orally. |
| DRUG | Zanubrutinib | Administered orally. |
| DRUG | Acalabrutinib | Administered orally. |
| DRUG | Venetoclax | Administered orally. |
Timeline
- Start date
- 2026-01-22
- Primary completion
- 2031-02-01
- Completion
- 2031-11-01
- First posted
- 2025-12-11
- Last updated
- 2026-04-15
Locations
20 sites across 5 countries: Australia, Brazil, Canada, New Zealand, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07277231. Inclusion in this directory is not an endorsement.